<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674501</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-1093</org_study_id>
    <nct_id>NCT04674501</nct_id>
  </id_info>
  <brief_title>Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON)</brief_title>
  <official_title>A Prospective Cohort Study of Patients Receiving Radiotherapy for Thoracic and Breast Cancer and the Related Cardiotoxicity Following Treatment (RACCOON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the risk factors and mechanisms of cardiotoxicity&#xD;
      following thoracic radiotherapy and to provide insights in preventing radiation-related&#xD;
      cardiotoxicity.&#xD;
&#xD;
      -Condition or disease : Thoracic irradiation -Intervention/treatment : Cardiac evaluation,&#xD;
      Blood sampling&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer patients who undergo thoracic irradiation receive a certain amount of dose to the&#xD;
      heart. Cardiotoxicity may occur in some patients several years after radiotherapy due to the&#xD;
      late effect of radiation. Considering that cardiotoxicity is often lethal, screening and&#xD;
      preventing radiation-induced cardiotoxicity is crucial in patients receiving thoracic&#xD;
      irradiation.&#xD;
&#xD;
      Patients in this cohort will undergo cardiac evaluation before and after thoracic&#xD;
      irradiation. The dose-volume parameters for each cardiac substructures will be estimated&#xD;
      using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume&#xD;
      parameters that predict cardiotoxicity will be analyzed. Among the patients who developed&#xD;
      cardiotoxicity, blood sampling will be performed to establish cardiomyocytes derived from&#xD;
      induced pluripotent stem cells, which will be used for identifying the mechanisms of&#xD;
      radiation-induced cardiotoxicity and therapeutic targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other toxicity rates</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Patients Who Receive Thoracic Irradiation</condition>
  <arm_group>
    <arm_group_label>Thoracic irradiation</arm_group_label>
    <description>A cohort of cancer patients who receive thoracic irradiation. Patients with any type of malignancy, such as lung cancer, breast cancer, esophageal cancer, or thymoma, are eligible as long as the patients undergo thoracic irradiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac evaluation and blood sampling</intervention_name>
    <description>Patients in this cohort will undergo cardiac evaluation before and after thoracic irradiation.&#xD;
The dose-volume parameters for each cardiac substructures will be estimated using artificial intelligence-based auto-segmentation of the heart in CT images. Dose-volume parameters that predict cardiotoxicity will be analyzed.&#xD;
The patients who developed cardiotoxicity will undergo blood sampling to establish cardiomyocytes derived from induced pluripotent stem cells, which will be used for identifying the mechanisms of radiation-induced cardiotoxicity and therapeutic targets.</description>
    <arm_group_label>Thoracic irradiation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with solid tumors who receive thoracic irradiation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with solid cancer who are subject to thoracic irradiation.&#xD;
&#xD;
          2. Patients who are 20 years old or older&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group Performance Status Scale 0-2&#xD;
&#xD;
          4. Patients with cognitive abilities to receive virtual reality information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of previous thoracic irradiation&#xD;
&#xD;
          2. Patients who refused consent&#xD;
&#xD;
          3. Patients with a history of heart failure before radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong In Yoon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong In Yoon</last_name>
    <phone>82-2-2228-8110</phone>
    <email>yhi0225@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong In Yoon</last_name>
      <phone>82-2-2228-8110</phone>
      <email>yhi0225@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 4, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

